Literature DB >> 22205054

Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study.

Richard Haynes1, Farhad Kheradmand, Christopher G Winearls.   

Abstract

BACKGROUND/AIMS: Adult polycystic kidney disease (ADPKD) has a predictable natural history and the relative lack of co-morbidity allows a relatively unconfounded assessment of survival. We examined whether survival on renal replacement treatment (RRT) has improved over the last four decades compared to that in the general population.
METHODS: We conducted a retrospective cohort study of all patients with ADPKD who received RRT between 1971 and 2000 at the Oxford Kidney Unit. The main exposure was period of start of treatment (1971-1985 vs. 1986-2000) and the key outcome was overall survival. Standard Cox regression techniques were used to assess the association between these baseline variables and survival.
RESULTS: Age at start of RRT (HR per 1 year 1.08; 95% CI 1.06-1.10) and presence of a functioning transplant (HR 0.22; 95% CI 0.16-0.31) were associated with improved survival in unadjusted analyses. After adjustment for age the period of treatment also became a significant predictor of overall survival (HR 0.67; 95% CI 0.47-0.97).
CONCLUSIONS: Survival on RRT appears to have improved and exceeds that observed in the general population, such that RRT now provides almost two-thirds of the life expectancy of the general population, compared to about half in earlier decades.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205054     DOI: 10.1159/000334429

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  6 in total

Review 1.  ADPKD: clinical issues before and after renal transplantation.

Authors:  Piergiorgio Messa; Carlo Maria Alfieri; Emanuele Montanari; Mariano Ferraresso; Roberta Cerutti
Journal:  J Nephrol       Date:  2016-10-20       Impact factor: 3.902

Review 2.  Current management of autosomal dominant polycystic kidney disease.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2015-09-06

Review 3.  Renal transplantation in autosomal dominant polycystic kidney disease.

Authors:  Nada Kanaan; Olivier Devuyst; Yves Pirson
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

4.  Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.

Authors:  Edwin M Spithoven; Anneke Kramer; Esther Meijer; Bjarne Orskov; Christoph Wanner; Jose M Abad; Nuria Aresté; Ramón Alonso de la Torre; Fergus Caskey; Cécile Couchoud; Patrik Finne; James Heaf; Andries Hoitsma; Johan de Meester; Julio Pascual; Maurizio Postorino; Pietro Ravani; Oscar Zurriaga; Kitty J Jager; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

5.  Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry.

Authors:  Víctor Martínez; Jordi Comas; Emma Arcos; Joan Manel Díaz; Salomé Muray; Juan Cabezuelo; José Ballarín; Elisabet Ars; Roser Torra
Journal:  BMC Nephrol       Date:  2013-09-05       Impact factor: 2.388

6.  Comparative Study of Outcomes among Patients with Polycystic Kidney Disease on Hemodialysis and Peritoneal Dialysis.

Authors:  Ju-Yeh Yang; Likwang Chen; Chia-Ter Chao; Yu-Sen Peng; Chih-Kang Chiang; Tze-Wah Kao; Kuo-Liong Chien; Hon-Yen Wu; Jenq-Wen Huang; Kuan-Yu Hung
Journal:  Sci Rep       Date:  2015-08-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.